| abstract |
Described are compositions and methods for administration of a fully human post-translationally modified therapeutic VEGF-Trap (HuPTM) (VEGFTrapHuPTMTM) to a human subject diagnosed with an ocular disease, eg, age-related macular degeneration (AMD) or condition or cancer. associated with neovascularization, eg, metastatic colon cancer, and indicated for treatment with the therapeutic mAb. Administration may suitably be accomplished by gene therapy, for example, by administering a viral vector, preferably AAV8 or AAV.7m8 variant, or other DNA expression construct encoding VEGF-TrapHuPTM™ to a patient (human subject) diagnosed with an ocular condition or cancer indicated for treatment with VEGF-Trap to create a permanent reservoir in a patient's tissue or organ that continuously supplies the VEGF-TrapHuPTM™, ie, a human glycosylated transgenic product. Alternatively, VEGF-TrapHuP™, eg, produced in culture from human cells grown, eg, in immortalized retinal or liver cells, can be administered to the patient for treatment of ocular disease or cancer. |